---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-019629"
form_type: "8-K"
ticker: "MNKD"
cik: "0000899460"
company_name: "MANNKIND CORP"
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T11:27:28.191125+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MannKind Q1 2023 total revenues $40.6M (+239% YoY); Tyvaso DPI drives $23M

## Summary
- Total revenues $40.6M vs $12.0M in Q1 2022, a 239% increase.
- Tyvaso DPI contributed $23M in revenue (collaborations/services $11.4M, royalties $11.7M).
- Afrezza net revenue $12.4M (+26% YoY); V-Go added $5.1M (acquired mid-2022).
- Loss from operations improved 72% to $6M; cash and investments $166.6M at March 31.
- CEO cites strong Tyvaso DPI demand; Phase 2/3 inhaled clofazimine trial to start H2 2023.

## SEC filing metadata
- accession: 0000950170-23-019629
- form_type: 8-K
- ticker: MNKD
- cik: 0000899460
- company_name: MANNKIND CORP
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899460/000095017023019629/0000950170-23-019629-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899460/000095017023019629/mnkd-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-019629
- JSON: https://secwatch.observer/filing/0000950170-23-019629.json
- Plain text: https://secwatch.observer/filing/0000950170-23-019629.txt

## Key facts
- Earnings Releases
  MANNKIND CORP reported the quarter ended March 31, 2023 results: revenue $41 million.
  - Period: the quarter ended March 31, 2023
  - Revenue: $41 million
  - Result: reported results
  source text: (EX-99.1) --- EX-99 EXHIBIT 99.1 MANNKIND CORPORATION REPORTS 2023 FIRST QUARTER FINANCIAL RESULTS Conference Call to Begin Today at 5:00 p.m. (ET) • 1Q 2023 Total Revenues of $41 million; +239% vs. 1Q 2022 • 1Q 2023 Revenues associated with Tyvaso DPI of $23 million • 1Q 2023 Loss from operations decreased 72% vs. 1Q 2022 to $6 million • $167 million of Cash,
  evidence_url: https://www.sec.gov/Archives/edgar/data/899460/000095017023019629/0000950170-23-019629-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.